Biotech | August 30, 2021
Vivo Bio Tech enters long-term contract with Bio E
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol
The segment delivered strong sales growth of 20% YoY
This is Enzene Biosciences third biosimilar to be approved
Blood samples were collected from 114 healthcare workers who received Covaxin in Chennai from February to May 2021
When used alongside rehabilitative exercise, this device may offer benefit to those who have lost function in their upper limbs due to ischemic stroke
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
The company has to approach the DCGI for approval to commence the trials
The clinical research organisation located in Hyderabad is a USFDA inspected facility
In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020
Subscribe To Our Newsletter & Stay Updated
